Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 6.5% in January

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 3,750,000 shares, a growth of 6.5% from the January 15th total of 3,520,000 shares. Based on an average trading volume of 925,600 shares, the days-to-cover ratio is currently 4.1 days.

Analyst Upgrades and Downgrades

IMUX has been the topic of several recent analyst reports. D. Boral Capital reaffirmed a "buy" rating and set a $17.00 price objective on shares of Immunic in a research report on Thursday. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research report on Monday, February 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Friday. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Immunic currently has an average rating of "Buy" and a consensus target price of $12.67.

Immunic Stock Up 6.6 %

NASDAQ:IMUX traded up $0.08 on Friday, hitting $1.26. The stock had a trading volume of 2,130,200 shares, compared to its average volume of 1,007,258. The stock has a market cap of $113.32 million, a price-to-earnings ratio of -1.02 and a beta of 1.87. The business's 50-day simple moving average is $1.02 and its two-hundred day simple moving average is $1.26. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Connor Clark & Lunn Investment Management Ltd. boosted its position in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after purchasing an additional 42,383 shares during the last quarter. State Street Corp lifted its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after buying an additional 11,642 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Immunic during the 3rd quarter valued at about $50,000. Finally, HB Wealth Management LLC purchased a new position in shares of Immunic during the 4th quarter valued at about $81,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.